Screening for Type 2 Diabetes Author: Lorraine Lipscombe, MD, FRCPC; Denice S. Feig, MD, MSc, FRCPC
Editorial changes - 2012-02-07
Author information and module status
Key Points
Population at Risk
Effectiveness/Harms of Screening Tests
Effectiveness/Harms of Early Treatment
Direct Evidence that Screening Reduces Adverse Outcomes
Timeline
Cost-Effectiveness
Patient Education
Referral/Consultation
Guidelines

Tables
References
Glossary
What's New
Patient Information
Additional Resources
Tools
Glossary
ACE
angiotensin-converting enzyme
ASA
acetylsalicylic acid
AROC
area under receiver operator curves
BMI
body mass index
BP
blood pressure
CAD
coronary artery disease
CBG
capillary blood glucose
CI
confidence interval
CVD
cardiovascular disease
FBG
fasting blood glucose
HDL
high-density lipoprotein
HMG-CoA
3-hydroxy-3-methylglutaryl coenzyme A
HbA1c
glycosylated hemoglobin
LDL
low-density lipoprotein
MI
myocardial infarction
NNT
number needed to treat
OGTT
oral glucose tolerance test
PG
postglucose
QALY
quality-adjusted life-year
RR
risk ratio
RRR
relative risk ratio
SD
standard deviation
Acronyms
ADA
American Diabetes Association
ALLHAT
Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
ASCOT
Anglo-Scandinavian Cardiac Outcomes Trial
CTF
Canadian Task Force on Preventive Medicine
HOT
Hypertension Optimal Treatment trial
MRC/BHF
Medical Research Council/British Heart Foundation
NCEP
National Cholesterol Education Program
NHANES III
Third National Health and Nutrition Examination Survey
SIGT
Screening for Glucose Tolerance Study
UKPDS
United Kingdom Prospective Diabetic Study
USPSTF
U.S. Preventive Services Task Force
Denice S. Feig, MD, MSc, FRCPC has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations. Lorraine Lipscombe, MD, FRCPC has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations. Sonal Singh, MD, editorial consultant, has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations.
Deborah Korenstein, MD, FACP, Co-Editor, PIER, has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations. Richard B. Lynn, MD, FACP, Co-Editor, PIER, has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations.


The information included herein should never be used as a substitute for clinical judgment and does not represent an official position of ACP. Because all PIER modules are updated regularly, printed web pages or PDFs may rapidly become obsolete. Therefore, PIER users should compare the date of the last update on the website with any printout to ensure that the information being referred to is the most current available.
PIER is copyrighted © 2012 by the American College of Physicians,
190 N. Independence Mall West, Philadelphia, PA 19106-1572, USA.